Related references
Note: Only part of the references are listed.Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Liver toxicity after treatment with gefitinib and anastrozole: Drug-drug interactions through cytochrome p450?
Paolo Carlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Elderly patients have become the leading drug consumers: It's high time to properly evaluate new drugs within the real targeted population
Lazzaro Repetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Is protracted low-dose temozolomide feasible in glioma patients?
A Tosoni et al.
NEUROLOGY (2006)
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience
W Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide:: A toxicity with therapeutic implications
YB Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Temozolomide in the treatment of recurrent malignant glioma
SM Chang et al.
CANCER (2004)
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium
E Everaert et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
One week on/one week off:: A novel active regimen of temozolomide for recurrent glioblastoma
W Wick et al.
NEUROLOGY (2004)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results
A Chahlavi et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
R Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M Brada et al.
ANNALS OF ONCOLOGY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)